236 related articles for article (PubMed ID: 24616382)
1. Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches.
Silsirivanit A; Sawanyawisuth K; Riggins GJ; Wongkham C
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):388-96. PubMed ID: 24616382
[TBL] [Abstract][Full Text] [Related]
2. A prospective proteomic-based study for identifying potential biomarkers for the diagnosis of cholangiocarcinoma.
Shi Y; Deng X; Zhan Q; Shen B; Jin X; Zhu Z; Chen H; Li H; Peng C
J Gastrointest Surg; 2013 Sep; 17(9):1584-91. PubMed ID: 23868055
[TBL] [Abstract][Full Text] [Related]
3. Proteomics analysis and evaluation of biomarkers for detection of cholangiocarcinoma.
Sriwanitchrak P; Viyanant V; Chaijaroenkul W; Srivatanakul P; Gram HR; Eursiddhichai V; Na-Bangchang K
Asian Pac J Cancer Prev; 2011; 12(6):1503-10. PubMed ID: 22126489
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous Analysis of Multiple Cancer Biomarkers Using MALDI-TOF Mass Spectrometry Based on a Parylene-Matrix Chip.
Park JM; Kim MJ; Noh JY; Yun TG; Kang MJ; Lee SG; Yoo BC; Pyun JC
J Am Soc Mass Spectrom; 2020 Apr; 31(4):917-926. PubMed ID: 32154716
[TBL] [Abstract][Full Text] [Related]
5. A Promising Serum Autoantibody Marker, Anti-Heat Shock Protein 90α, for Cholangiocarcinoma.
Boonjaraspinyo S; Juasook A; Boonmars T; Aukkanimart R; Silsirivanit A; Loilome W; Sriraj P; Wu Z; Ratanasuwan P
Asian Pac J Cancer Prev; 2015; 16(14):5779-85. PubMed ID: 26320451
[TBL] [Abstract][Full Text] [Related]
6. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
[TBL] [Abstract][Full Text] [Related]
7. Characterization of apolipoprotein A-I as a potential biomarker for cholangiocarcinoma.
Wang X; Dai S; Zhang Z; Liu L; Wang J; Xiao X; He D; Liu B
Eur J Cancer Care (Engl); 2009 Nov; 18(6):625-35. PubMed ID: 19486127
[TBL] [Abstract][Full Text] [Related]
8. Plasma phosphoproteome and differential plasma phosphoproteins with opisthorchis viverrini-related cholangiocarcinoma.
Kotawong K; Thitapakorn V; Roytrakul S; Phaonakrop N; Viyanant V; Na-Bangchang K
Asian Pac J Cancer Prev; 2015; 16(3):1011-8. PubMed ID: 25735322
[TBL] [Abstract][Full Text] [Related]
9. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.
Sandim V; Pereira Dde A; Kalume DE; Oliveira-Carvalho AL; Ornellas AA; Soares MR; Alves G; Zingali RB
Urol Oncol; 2016 Jan; 34(1):5.e11-25. PubMed ID: 26420021
[TBL] [Abstract][Full Text] [Related]
10. A novel serum carbohydrate marker on mucin 5AC: values for diagnostic and prognostic indicators for cholangiocarcinoma.
Silsirivanit A; Araki N; Wongkham C; Pairojkul C; Narimatsu Y; Kuwahara K; Narimatsu H; Wongkham S; Sakaguchi N
Cancer; 2011 Aug; 117(15):3393-403. PubMed ID: 21287531
[TBL] [Abstract][Full Text] [Related]
11. Serum α1β-glycoprotein and afamin ratio as potential diagnostic and prognostic markers in cholangiocarcinoma.
Tolek A; Wongkham C; Proungvitaya S; Silsirivanit A; Roytrakul S; Khuntikeo N; Wongkham S
Exp Biol Med (Maywood); 2012 Oct; 237(10):1142-9. PubMed ID: 23104505
[TBL] [Abstract][Full Text] [Related]
12. Banking on the future: biobanking for "omics" approaches to biomarker discovery for Opisthorchis-induced cholangiocarcinoma in Thailand.
Mulvenna J; Yonglitthipagon P; Sripa B; Brindley PJ; Loukas A; Bethony JM
Parasitol Int; 2012 Mar; 61(1):173-7. PubMed ID: 21855650
[TBL] [Abstract][Full Text] [Related]
13. A Novel Serum Glycobiomarker for Diagnosis and Prognosis of Cholangiocarcinoma Detected by
Teeravirote K; Luang S; Waraasawapati S; Boonsiri P; Wongkham C; Wongkham S; Silsirivanit A
Molecules; 2021 May; 26(9):. PubMed ID: 34066878
[TBL] [Abstract][Full Text] [Related]
14. Possible involvement of cyclophilin A processing in fumagillin-induced suppression of cholangiocarcinoma cell proliferation.
Sawanyawisuth K; Wongkham C; Riggins GJ; Wongkham S; Araki N
Asian Pac J Cancer Prev; 2012; 13 Suppl():137-41. PubMed ID: 23480755
[TBL] [Abstract][Full Text] [Related]
15. Urine proteomics study reveals potential biomarkers for the differential diagnosis of cholangiocarcinoma and periductal fibrosis.
Duangkumpha K; Stoll T; Phetcharaburanin J; Yongvanit P; Thanan R; Techasen A; Namwat N; Khuntikeo N; Chamadol N; Roytrakul S; Mulvenna J; Mohamed A; Shah AK; Hill MM; Loilome W
PLoS One; 2019; 14(8):e0221024. PubMed ID: 31425520
[TBL] [Abstract][Full Text] [Related]
16. Proteomics-based identification of α-enolase as a potential prognostic marker in cholangiocarcinoma.
Yonglitthipagon P; Pairojkul C; Bhudhisawasdi V; Mulvenna J; Loukas A; Sripa B
Clin Biochem; 2012 Jul; 45(10-11):827-34. PubMed ID: 22552009
[TBL] [Abstract][Full Text] [Related]
17. Biomarker discovery for kidney diseases by mass spectrometry.
Niwa T
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jul; 870(2):148-53. PubMed ID: 18024247
[TBL] [Abstract][Full Text] [Related]
18. Identification of potential plasma biomarkers for esophageal squamous cell carcinoma by a proteomic method.
Zhao J; Fan YX; Yang Y; Liu DL; Wu K; Wen FB; Zhang CY; Zhu DY; Zhao S
Int J Clin Exp Pathol; 2015; 8(2):1535-44. PubMed ID: 25973038
[TBL] [Abstract][Full Text] [Related]
19. Analysis of new biomarkers for cholangiocarcinoma.
Miwa M; You G; Tanaka H; Taniguchi S; Fujii T; Kamemura K; Suzaki M; Isono T; Tooyama I; Tanaka M; Srivatanakul P; Viwatthanasittiphong C; Sangrajrang S; Khuhaprema T
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):397-8. PubMed ID: 24446393
[TBL] [Abstract][Full Text] [Related]
20. Identification of TPD52 and DNAJB1 as two novel bile biomarkers for cholangiocarcinoma by iTRAQ‑based quantitative proteomics analysis.
Ren H; Luo M; Chen J; Zhou Y; Li X; Zhan Y; Shen D; Chen B
Oncol Rep; 2019 Dec; 42(6):2622-2634. PubMed ID: 31661142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
